Upgrade to SI Premium - Free Trial

Form 8-K QuidelOrtho Corp For: Jun 16

June 16, 2026 4:32 PM
QuidelOrtho Corp false 0001906324 0001906324 2026-06-16 2026-06-16
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 16, 2026

 

 

QUIDELORTHO CORPORATION

(Exact name of Registrant as specified in its Charter)

 

 

 

Delaware   001-41409   87-4496285

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

9975 Summers Ridge Road, San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 552-1100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 Par Value   QDEL   The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 16, 2026, QuidelOrtho Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The following are the final voting results on proposals considered and voted upon at the Annual Meeting, all of which are described in the proxy statement for the Annual Meeting, as filed with the U.S. Securities and Exchange Commission on April 27, 2026.

Proposal No. 1

The Company’s stockholders elected the ten director nominees to the Company’s Board of Directors by the votes set forth in the table below:

 

Name   Votes For   Votes Withheld   Broker Non-Votes

Brian J. Blaser

  56,664,418   560,787   7,088,721

Kenneth F. Buechler, Ph.D.

  56,008,344   1,216,861   7,088,721

John R. Chiminski

  56,788,541   436,664   7,088,721

Evelyn S. Dilsaver

  56,676,148   549,057   7,088,721

R. Scott Huennekens

  56,634,433   590,772   7,088,721

Edward L. Michael

  56,585,483   639,722   7,088,721

Mary Lake Polan, M.D., Ph.D., M.P.H.

  56,148,684   1,076,521   7,088,721

Ann D. Rhoads

  56,741,863   483,342   7,088,721

Kenneth J. Widder, M.D.

  56,078,638   1,146,567   7,088,721

Joseph D. Wilkins Jr.

  56,587,197   638,008   7,088,721

Proposal No. 2

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by the votes set forth in the table below:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
55,716,067   1,486,910   22,228   7,088,721

Proposal No. 3

The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the Company’s 2026 fiscal year by the votes set forth in the table below:

 

Votes For   Votes Against   Abstentions
64,197,113   97,367   19,446


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 16, 2026

 

QUIDELORTHO CORPORATION
By:  

/s/ Nathaniel B. Sisitsky

Name:   Nathaniel B. Sisitsky
Its:   Chief Legal Officer and Corporate Secretary

ATTACHMENTS / EXHIBITS

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: d113744d8k_htm.xml

Categories

SEC Filings